CA-ALKIRA
Alkira Inc. has appointed Exclusive Networks, a global trusted cybersecurity specialist for digital infrastructure, as a distributor for its cloud networking as-a-service platform (CNaaS).
The deal makes Alkira’s CNaaS platform Cloud Services Exchange (CSX) available through Exclusive’s global partner ecosystem spanning 40 countries across five continents. It also underlines Exclusive’s commitment to growing its cloud portfolio in a market estimated by IDC to be on track for $1.3 trillion by 20251 .
Exclusive Networks (EXN), which posted gross sales of €2.9 billion in 2020, completed a successful Initial Public Offering and listing on Euronext Paris in September this year. The company has partnerships with some of the world’s largest and most successful cybersecurity, networking and cloud infrastructure vendors, including Fortinet, Nutanix, Palo Alto Networks, Rubrik and Sentinel One. It provides cybersecurity platforms, cloud solutions and associated value-add professional services through an extensive global partner network of specialist resellers, MSPs, CSPs, telcos and systems integrators.
Alkira has appointed Paul Couturier as Senior VP International to spearhead its expansion in the EMEA and APAC regions. Couturier is an IT industry veteran who has previously held senior management roles growing international markets for Efficient Networks, TippingPoint, Cyan, LightCyber and Palo Alto Networks. In his latest role, he managed IntSights from its European debut to its acquisition by Rapid 7.
Amir Khan, Co-Founder and Chief Executive Officer of Alkira, said: “Our vision is to simplify networking in the cloud era. As the CNaaS pioneer, Alkira has eliminated the complexities and costs of building and operating networks and seamlessly integrated cloud, multi-cloud and legacy systems – no hardware, no data center, no need to ship anything. Exclusive Networks is an ideal partner for Alkira, not only because it provides us with access to their first-class global network, but because we have a shared vision of an as-a-service future.”
Andy Travers, Executive Vice President, Worldwide Sales and Marketing for Exclusive Networks, said: “Our success has been built on bringing together best in class cybersecurity, networking and automation solutions. In the cloud era, the challenge for customers is how to integrate and manage these resources in an increasingly complex environment, while controlling costs and moving the business forward. With nothing more than a few mouse clicks, Alkira’s CNaaS enables secure hybrid cloud and multi-cloud networks to be set up in hours rather than months, and puts customers, not the big cloud providers, in the driver’s seat.
“Migration of enterprise applications to the cloud is set to double in the next two years, according to Gartner2 , so it seems inevitable that networking infrastructure will follow the same trend. Just as Alkira’s founders pioneered the SD-WAN market, we now believe they are showing the way in cloud networking.”
Alkira’s CNaaS platform simplifies provisioning, connectivity and end-to-end management of networks across cloud environments, including the integration of firewalls, IPS/IDS, and load balancers, as well as enhancing the capabilities of legacy SD-WAN solutions. It enables a flexible, unified approach to secure, high-performance networking in which customers only pay for the capacity they use, and the network automatically scales to meet changing patterns of usage and demand.
About Alkira
Alkira® developed the Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira CSX seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of integrated solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.alkira.com or follow us @AlkiraNet
(Alkira® and Alkira Cloud Services Exchange® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.)
About Exclusive Networks
Exclusive Networks is a global trusted cybersecurity specialist for digital infrastructure helping to drive the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models. The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to deliver partner value. With offices in 40 countries and the ability to service customers in over 150 countries across five continents, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. Learn more at www.exclusive-networks.com or follow us @EXN_Networks
1
IDC Forecasts Worldwide "Whole Cloud" Spending to Reach $1.3 Trillion by 2025
2
Market Guide to Cloud Networking Software, Gartner, May 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom